Mutant p53 Protein Is Targeted by Arsenic for Degradation and Plays a Role in Arsenic-mediated Growth Suppression

Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2

(2011) Xiaosong Wu et al.   CANCER BIOLOGY & THERAPY

PML/RARA Oxidation and Arsenic Binding Initiate the Antileukemia Response of As2O3

(2010) Marion Jeanne et al.   CANCER CELL

Characterization of Functional Domains Necessary for Mutant p53 Gain of Function

(2010) Wensheng Yan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector

(2010) J. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Arsenic Trioxide Controls the Fate of the PML-RAR  Oncoprotein by Directly Binding PML

(2010) X. W. Zhang et al.   SCIENCE

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

(2009) Jeremy M.R. Lambert et al.   CANCER CELL

Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53

(2009) S. Haupt et al.   CANCER RESEARCH

The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: A systematic review

(2009) Christoph Röllig et al.   CANCER TREATMENT REVIEWS

Mutant p53 Drives Invasion by Promoting Integrin Recycling

(2009) Patricia A.J. Muller et al.   CELL

Biological Responses to Arsenic Compounds

(2009) Leonidas C. Platanias   JOURNAL OF BIOLOGICAL CHEMISTRY

Identification of GRO1 as a Critical Determinant for Mutant p53 Gain of Function

(2009) Wensheng Yan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia

(2009) Q.-Y. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer

(2009) J. P. Morton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Suppression of Inhibitor of Differentiation 2, a Target of Mutant p53, Is Required for Gain-of-Function Mutations

(2008) W. Yan et al.   CANCER RESEARCH

TAp73 knockout shows genomic instability with infertility and tumor suppressor functions

(2008) R. Tomasini et al.   GENES & DEVELOPMENT

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss

(2008) T. Terzian et al.   GENES & DEVELOPMENT

Cooperative Roles of c-Abl and Cdk5 in Regulation of p53 in Response to Oxidative Stress

(2008) Jong-Hee Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Arsenic trioxide mechanisms of action – looking beyond acute promyelocytic leukemia

(2008) Dennis A. Carney   LEUKEMIA & LYMPHOMA

Arsenic trioxide decreases AKT protein in a caspase-dependent manner

(2008) Koren K. Mann et al.   MOLECULAR CANCER THERAPEUTICS

Arsenic degrades PML or PML–RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway

(2008) Valérie Lallemand-Breitenbach et al.   NATURE CELL BIOLOGY